secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
CIK:        0001500198
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001213900-23-038538
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroOne Q2 product revenue surges to $466K; net loss $3.5M; Evo sEEG launched
------------------------------------------------------------------------------

- Product revenue $466K in Q2 (vs $37K YoY); collaboration revenue $1.46M first half from Zimmer deal.
- Net loss $3.5M for Q2 vs $3.1M prior year; operating expenses rose to $3.5M.
- Cash and equivalents $4.6M as of Mar 31, down from $11.1M at Sep 30; no debt.
- Commercial launch of Evo sEEG electrode with Zimmer Biomet; first cases at Mayo and Cleveland Clinic.
- On track to submit 510(k) for OneRF ablation system in Q2 calendar 2023; new VP of Operations appointed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1500198/000121390023038538/0001213900-23-038538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1500198/000121390023038538/ea178248-8k_neuroone.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-038538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer